Johnson & Johnson $JNJ Stake Lowered by Mawer Investment Management Ltd.

Mawer Investment Management Ltd. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 16.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 270,951 shares of the company’s stock after selling 51,526 shares during the quarter. Mawer Investment Management Ltd.’s holdings in Johnson & Johnson were worth $71,732,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of JNJ. MSH Capital Advisors LLC lifted its stake in Johnson & Johnson by 1.8% in the third quarter. MSH Capital Advisors LLC now owns 22,979 shares of the company’s stock valued at $6,083,000 after buying an additional 415 shares during the period. Ibex Wealth Advisors boosted its holdings in Johnson & Johnson by 7.4% during the third quarter. Ibex Wealth Advisors now owns 3,988 shares of the company’s stock worth $1,056,000 after buying an additional 276 shares during the last quarter. Clearwater Capital Advisors LLC grew its position in shares of Johnson & Johnson by 1.3% during the 3rd quarter. Clearwater Capital Advisors LLC now owns 3,650 shares of the company’s stock worth $966,000 after buying an additional 47 shares during the period. AlpenGlobal Capital LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth about $2,608,000. Finally, Wellington Grp LLC increased its stake in shares of Johnson & Johnson by 15.1% in the 3rd quarter. Wellington Grp LLC now owns 1,047 shares of the company’s stock valued at $277,000 after acquiring an additional 137 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Recent Johnson & Johnson Headlines

Investors following JNJ have been watching these headlines:

• Positive Sentiment: JNJ has risen 10.4% since its latest earnings report, and State Street’s Health Care SPDR added shares on Nov. 10. These reports suggest continued investor interest, though neither guarantees further gains. Johnson & Johnson Up 10.4% Since Last Earnings Report State Street Health Care SPDR Adds Johnson & Johnson
• Neutral Sentiment: J&J also led a $100 million funding round for Delix Therapeutics’ depression-drug development. This broadens its exposure to emerging psychiatric treatments, but clinical-stage programs carry substantial execution risk. Johnson & Johnson Backs New Cancer Device And Leads $100 Million Depression Bet
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of J&J investors. The notice provides no specific findings, but litigation-related uncertainty may weigh on sentiment. Pomerantz Law Firm Investigates Claims on Behalf of Johnson & Johnson Investors

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Johnson Rice downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a research note on Monday, August 3rd. Erste Group Bank cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, October 21st. UBS Group set a $270.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 14th. Finally, Evercore set a $300.00 target price on shares of Johnson & Johnson in a report on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $275.92.

Johnson & Johnson Stock Up 0.8%

Shares of NYSE JNJ traded up $2.26 during mid-day trading on Friday, reaching $285.78. 6,279,519 shares of the company’s stock were exchanged, compared to its average volume of 7,472,752. Johnson & Johnson has a twelve month low of $193.55 and a twelve month high of $288.11. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $687.95 billion, a price-to-earnings ratio of 43.30, a PEG ratio of 2.80 and a beta of 0.22. The business has a fifty day simple moving average of $266.97 and a 200 day simple moving average of $249.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same period in the previous year, the firm earned $2.80 EPS. Johnson & Johnson’s quarterly revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities analysts expect that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson’s payout ratio is presently 81.21%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 61,669 shares of company stock valued at $16,898,386. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.